Public, NASDAQ:HEPH
NASDAQ Global Market
Hollis-Eden initiates Phase II diabetes trial
Date: Thu, 17 Jul 2008 13:11:17 GMT
Tags:
Hollis-Eden initiates Phase II diabetes trial
Trading Markets (press release) - Jul 17, 2008
Trading Markets (press release) - Jul 17, 2008
Jul 17 , 2008 ( Datamonitor via COMTEX ) - - HEPH | Quote | Chart | News | PowerRating - - Hollis - Eden Pharmaceuticals has started a Phase II clinical trial with its oral drug candidate Triolex ...
Hollis-Eden starts Phase II trial with Triolex in type-2 diabetes patients
Date: Wed, 16 Jul 2008 13:35:54 GMT
Tags:
Hollis-Eden starts Phase II trial with Triolex in type-2 diabetes patients
RTT News - Jul 16, 2008
RTT News - Jul 16, 2008
( RTTNews ) - Wednesday , Hollis - Eden Pharmaceuticals , Inc . ( HEPH : News , Chart , Quote ) , a developer of proprietary class of adrenal steroid hormones , announced that it has started ...
Hollis-Eden reports additional positive data from Triolex Phase I/II trial
Date: Mon, 09 Jun 2008 12:59:48 GMT
Tags:
Hollis-Eden reports additional positive data from Triolex Phase I/II trial
Forbes - Jun 9, 2008
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Monday, June 9th QMCI, GSPG, CPWM, HEPH, MYEC - Trading Markets (press release)
RTT News
Forbes - Jun 9, 2008
BOSTON ( Thomson Financial ) - Hollis - Eden Pharmaceuticals Inc . Monday reported additional positive data from its on - going Phase I / II clinical trial with Triolex supporting an anti - inflammatory ...
Hollis-Eden Pharma Reports Additional Positive Data from Phase I/II Clinical Trial with Triolex - RTT NewsOTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Monday, June 9th QMCI, GSPG, CPWM, HEPH, MYEC - Trading Markets (press release)
RTT News
Hollis - Eden Pharma reports narrower net loss in Q1; updates clinical development programs
Date: Tue, 13 May 2008 13:25:31 GMT
Tags:
Hollis - Eden Pharma reports narrower net loss in Q1; updates clinical development programs
RTT News - May 13, 2008
RTT News - May 13, 2008
( RTTNews ) - Tuesday , San Diego , California - based development stage pharma company Hollis - Eden Pharmaceuticals Inc . ( HEPH : News , Chart , Quote ) announced a narrower net loss for the ...
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces First Quarter 2008 Financial Results - Business Wire (press release)Hollis-Eden Q1 Loss narrows; issues Update on Clinical Development Programs - Quick Facts
Date: Tue, 13 May 2008 11:21:26 GMT
Tags:
Hollis-Eden Q1 Loss narrows; issues Update on Clinical Development Programs - Quick Facts
RTT News - May 13, 2008
RTT News - May 13, 2008
( RTTNews ) - Hollis - Eden Pharmaceuticals , Inc . ( HEPH : News , Chart , Quote ) on Tuesday announced financial results for the first quarter , posting a net loss of $5.7 million or $0.20 ...
[$$] Research Reports (at Barron's Online)
Date: Sat, 19 Jul 2008 10:47:00 Etc/GMT
Tags:
Comments from investment analysts on several companies, each with buy/hold/sell recommendations.
Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX(TM) (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment (Business Wire)
Date: Wed, 16 Jul 2008 11:00:00 Etc/GMT
Tags:
SAN DIEGO----Hollis-Eden Pharmaceuticals, Inc. , the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it has commenced a Phase II clinical trial with its oral drug candidate TRIOLEX⢠in type 2 diabetes patients, and that it is expanding the number of clinical sites to accelerate enrollment.
HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)
Date: Tue, 10 Jun 2008 20:31:07 Etc/GMT
Tags:
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX(TM) Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes (Business Wire)
Date: Mon, 9 Jun 2008 11:00:00 Etc/GMT
Tags:
SAN DIEGO----Hollis-Eden Pharmaceuticals, Inc. today announced additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate TRIOLEX , supporting the potential benefit of a novel anti-inflammatory approach to improving insulin sensitivity in patients with type 2 diabetes.
New Star Analyst Rankings for HOLLIS-EDEN PHARM (StarMine)
Date: Wed, 14 May 2008 15:09:25 Etc/GMT
Tags: